Captozyme to sponsor the OHF’s 2019 Hyperoxaluria Workshop
Seven years ago Helena Cowley, CEO of Captozyme, a Florida-based microbiome and enzyme company, attended a conference that would help shape the destiny of the company she would someday lead.
During the 2012 Oxalosis & Hyperoxaluria Foundation (OHF) International Hyperoxaluria Workshop, a yearly educational gathering bringing together patients of rare diseases and their families, Cowley attended the keynote delivered by a mother who lost her child to a rare condition called oxalosis. The story touched her, as well as company co-founders Aaron Cowley and Qing-Shan, and helped the trio focus their efforts on researching and developing an enzyme that could improve the lives of patients with oxalosis and hyperoxaluria.
This year, Captozyme will participate in the 2019 OHF International Hyperoxaluria Workshop in Boston as a sponsor. Ira Klimberg, M.D., medical monitor of the recent clinical study for Ox-1, will join Cowley at the workshop and present the Captozyme clinical study results during a panel discussion on Saturday, June 22.
“We are honored to be one of the Workshop sponsors and to do our part alongside academia and industry to further the understanding of these disease and drive progress towards treatments,” Cowley said.
Ox-1, distributed nationwide by Captozyme’s subsidiary, Entring, LLC as Nephure, is the result of more than a decade of work. In August 2018, Captozyme sponsored the first human clinical study of the oxalate-reducing enzyme and found it effective in 94% of healthy study subjects. Study results were presented at the American Urological Association Annual Meeting in May 2019 and will be published in a peer reviewed journal later this year.
“We are delighted to share these results with researchers, patients living with these diseases and their families. Our study confirmed the efficacy and potency of our oxalate-reducing enzyme to reduce urinary oxalate, and we believe this will be welcome news,” Dr. Klimberg remarked.